Cover Image
市場調查報告書

缺血性心臟疾病 (IHD) 治療藥的全球市場 (2015-2019年)

Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 336501
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
Back to Top
缺血性心臟疾病 (IHD) 治療藥的全球市場 (2015-2019年) Global Ischemic Heart Disease (IHD) Drugs Market 2015-2019
出版日期: 2015年07月29日 內容資訊: 英文 113 Pages
簡介

缺血性心臟疾病 (IHD) ,特徵為心臟供給血液的動脈收縮或閉塞,人身體中的異常狀態,起因於動脈內的斑塊 (血小板) 積蓄。這個狀態,傾向在興奮時及運動時心臟須供給更多血液的情況下產生,無法充分供給血液,造成伴隨心絞痛這種反復性胸部疼痛及不舒服的狀態。持續血液供不應求的動脈閉塞狀態的話,心臟的組織會壞死,引起心肌梗塞。因應患者的狀態有不同的治療選項關於,藥物給藥,可選擇Statin,抗血小板藥,硝酸酯,β- 阻斷劑等,多樣種類的藥物。Technavio的分析師預測,全球IHD治療藥市場從2014年到2019年以年複合成長率 (CAGR) 3.61%成長。

本報告以全球缺血性心臟疾病 (IHD) 治療藥市場為主題,提供市場概要、市場發展推動因素、市場課題和那些的影響、各疾病分類、各藥物分類、各地區的市場現況與展望相關調查分析,主要的供應商分析彙整。

第1章 摘要整理

第2章 簡稱集

第3章 調查範圍

  • 市場概要
  • 提供產品

第4章 市場調查手法

  • 市場調查的過程
  • 調查手法

第5章 簡介

第6章 疾病概要

  • 理解疾病
  • 病因和危險因素
    • 可修正的危險因素
    • 無法修正的危險因素
  • 病理學
  • 徵兆與症狀
  • 診斷
    • ECG (心電圖)
    • 負擔試驗
    • 心臟超音波檢驗
    • 胸部X光掃描
    • 血液檢驗
    • 冠動脈攝影術法和心導管法
  • 管理
    • 生活方式的變化
    • 藥物療法
    • 醫療治療
  • 流行病學
  • 經濟負擔

第7章 開發平台分析

  • 開發平台候補相關資訊
    • ONO-1101
    • Ranolazine
    • 自我移植CD34+幹細胞
    • Generx
    • Cryocell (細胞冷凍保存)
    • RVX-208
    • MPSK3169A
    • GS-6615
    • JVS-100
    • LA-419
    • ALD-201

第8章 市場形勢

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第9章 市場區隔,各疾病分類

  • 心絞痛
    • 穩定心絞痛
    • 不穩定心絞痛
    • 變異型心絞痛
  • MI (心肌梗塞)
    • STEMI (ST上升型心肌梗塞)
    • NSTEMI (非ST上升型心肌梗塞)

第10章 市場區隔,各藥物分類

  • 抗血脂異常症藥
  • 鈣離子阻斷劑
  • β- 阻斷劑
  • ACE (血管收縮素轉化酵素) 抑制劑
  • ARB (血管收縮素受體抑制劑)
  • 血管擴張劑
  • 抗血栓劑

第11章 各地區區分

第12章 購買條件

第13章 推動市場成長要素

第14章 推動因素與其影響

第15章 市場上課題

第16章 推動因素與課題的影響

第17章 市場趨勢

第18章 趨勢與其影響

第19章 業者情勢

  • 競爭模式
    • 主要消息
    • 合併、收購
  • 市場佔有率分析,2014年
    • AstraZeneca
    • Bayer
    • Eli Lilly
    • Novartis
    • Pfizer
    • Sanofi

第20章 全球IHD治療藥市場:主要調查結果

第21章 主要供應商分析 (主要的資訊、產業概要、各產業分類銷售額、各區域銷售額、產業策略、最近的趨勢、SWOT分析)

  • AstraZeneca plc
  • Bayer
  • Eli Lilly
  • Novartis AG
  • Pfizer
  • Sanofi SA

第22章 本系列其他報告

圖表清單

目錄
Product Code: IRTNTR6611

About IHD

IHD is an abnormal condition of the human body marked by narrowing or blocking of the arteries that supply blood to the heart. It results from the buildup of plaque in the arteries. The condition often arises during excitement and exertion when heart requires more blood supply. This leads to recurrent chest pain and discomfort due to lack of sufficient blood supply, a condition known as angina pectoris.

Prolonged blockage of the arteries due to lack of blood supply may result in death of tissues in the heart, leading to myocardial infarction. The symptoms develop slowly, and in most cases the condition is asymptomatic until it reaches the last stages. The common indications include chest pain and shortness of breath. Treatment options are available depending on the condition of the patient. A range of medications of different classes, such as statins, antiplatelet drugs, nitrates, beta-blockers, etc. can be chosen from. Surgical procedures, such as angioplasty and coronary artery bypass graft, are also opted in serious scenarios.

Technavio analysts forecast the global IHD drugs market to grow at a CAGR of 3.61% during 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the global IHD drugs market for the period 2015-2019. To calculate the market size, we consider the revenue generated from the sales of various branded therapies and generics, along with the drugs used as off-label for the treatment of IHD. IHD includes:

  • Angina pectoris
  • Myocardial infarction.

The Technavio report, namely Global IHD Drugs Market 2015-2019, is based on an in-depth market analysis, with inputs from industry experts. We covers the Americas, APAC and EMEA markets. We also discuss the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • AstraZeneca
  • Bayer
  • Eli Lilly
  • Novartis
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Actelion
  • Amgen
  • Baxter
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi-Sankyo
  • Eisai
  • F.Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline
  • Human Stem Cells Institute
  • Janssen Pharmaceuticals
  • Juventas Therapeutics
  • Lacer
  • Merck
  • Nuo Therapeutics
  • Ono Pharmaceutical
  • Pharmahungary Group
  • Resverlogix
  • Takeda Pharmaceutical Company
  • Taxus Cardium
  • The Medicines Company
  • United Therapeutics

Market Driver

  • Rise in Number of Patients
  • For a full and detailed list, view our report

Market Challenge

  • Delayed Diagnosis
  • For a full and detailed list, view our report

Market Trend

  • Increase in Health Awareness
  • For a full and detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

  • 06.1. Understanding the Disease
  • 06.2. Etiology and Risk Factors
    • 06.2.1. Modifiable Risk Factors
    • 06.2.2. Non-modifiable Risk Factors
  • 06.3. Pathophysiology
  • 06.4. Signs and Symptoms
  • 06.5. Diagnosis
    • 06.5.1. ECG
    • 06.5.2. Stress Testing
    • 06.5.3. Echocardiography
    • 06.5.4. Chest X-Ray
    • 06.5.5. Blood Tests
    • 06.5.6. Coronary Angiography and Cardiac Catheterization
  • 06.6. Management
    • 06.6.1. Lifestyle Changes
    • 06.6.2. Pharmacotherapy
    • 06.6.3. Medical Procedures
  • 06.7. Epidemiology
  • 06.8. Economic Burden

07. Pipeline Analysis

  • 07.1. Information on Pipeline Candidates
    • 07.1.1. ONO-1101
    • 07.1.2. Ranolazine
    • 07.1.3. Autologous CD34+ stem cells
    • 07.1.4. Generx
    • 07.1.5. Cryocell
    • 07.1.6. RVX-208
    • 07.1.7. MPSK3169A
    • 07.1.8. GS-6615
    • 07.1.9. JVS-100
    • 07.1.10. LA-419
    • 07.1.11. ALD-201

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Disease Class

  • 09.1. Angina Pectoris
    • 09.1.1. Stable Angina
    • 09.1.2. Unstable Angina
    • 09.1.3. Prinzmetal's Angina
  • 09.2. MI
    • 09.2.1. STEMI
    • 09.2.2. NSTEMI

10. Market Segmentation by Drug Class

  • 10.1. Anti-dyslipidemic Drugs
  • 10.2. Calcium Channel Blockers
  • 10.3. Beta-blockers
  • 10.4. ACE Inhibitors
  • 10.5. ARBs
  • 10.6. Vasodilators
  • 10.7. Antithrombotic Agents

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
    • 19.2.1. AstraZeneca
    • 19.2.2. Bayer
    • 19.2.3. Eli Lilly
    • 19.2.4. Novartis
    • 19.2.5. Pfizer
    • 19.2.6. Sanofi
  • 19.3. Other and Future Prominent Vendors

20. Global IHD Drugs Market: Key Takeaways

21. Key Vendor Analysis

  • 21.1. AstraZeneca plc
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation by Revenue 2013
    • 21.1.4. Business Segmentation by Revenue 2011-2013
    • 21.1.5. Sales by Geography
    • 21.1.6. Business Strategy
    • 21.1.7. Key Developments
    • 21.1.8. SWOT Analysis
  • 21.2. Bayer
    • 21.2.1. Key facts
    • 21.2.2. Business overview
    • 21.2.3. Business segmentation by revenue 2014
    • 21.2.4. Business segmentation by revenue 2013 and 2014
    • 21.2.5. Geographical segmentation by revenue 2014
    • 21.2.6. Business strategy
    • 21.2.7. Recent developments
    • 21.2.8. SWOT analysis
  • 21.3. Eli Lilly
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation by Revenue
    • 21.3.4. Sales by Geography
    • 21.3.5. Business Strategy
    • 21.3.6. Key Information
    • 21.3.7. SWOT Analysis
  • 21.4. Novartis AG
    • 21.4.1. Key Facts
    • 21.4.2. Business Description
    • 21.4.3. Business Segmentation
    • 21.4.4. Revenue by Business Segmentation
    • 21.4.5. Revenue Comparison 2012 and 2013
    • 21.4.6. Sales by Geography
    • 21.4.7. Business Strategy
    • 21.4.8. Key Developments
    • 21.4.9. SWOT Analysis
  • 21.5. Pfizer
    • 21.5.1. Key facts
    • 21.5.2. Business overview
    • 21.5.3. Business segmentation by revenue 2014
    • 21.5.4. Business segmentation by revenue 2013 and 2014
    • 21.5.5. Geographical segmentation by revenue 2014
    • 21.5.6. Business strategy
    • 21.5.7. Key developments
    • 21.5.8. SWOT analysis
  • 21.6. Sanofi SA
    • 21.6.1. Key Facts
    • 21.6.2. Business Description
    • 21.6.3. Business Segmentation
    • 21.6.4. Revenue by Business Segmentation
    • 21.6.5. Revenue Comparison 2012 and 2013
    • 21.6.6. Sales by Geography
    • 21.6.7. Business Strategy
    • 21.6.8. Key Developments
    • 21.6.9. SWOT Analysis

22. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Overview of IHD
  • Exhibit 3: Pathophysiology of IHD
  • Exhibit 4: Leading Cause of Death in World 2012
  • Exhibit 5: Leading Cause of Death in US 2013
  • Exhibit 6: Pipeline Portfolio of IHD Drugs
  • Exhibit 7: Global IHD Drugs Market 2014-2019 ($ millions)
  • Exhibit 8: Global IHD Drugs Market Segment by Disease Class
  • Exhibit 9: Global IHD Drugs Market Segment by Drug Class
  • Exhibit 10: Segmentation of Global IHD Drugs Market by Geography 2014
  • Exhibit 11: YoY Growth and Revenue of Atacand 2010-2014 ($ millions)
  • Exhibit 12: YoY Growth and Revenue of Crestor 2010-2014 ($ millions)
  • Exhibit 13: YoY Growth and Revenue of Seloken/Toprol-XL 2010-2014 ($ millions)
  • Exhibit 14: YoY Growth and Revenue of Adalat 2010-2014 ($ millions)
  • Exhibit 15: YoY Growth and Revenue of Xarelto 2010-2014 ($ millions)
  • Exhibit 16: YoY Growth and Revenue of Effient 2010-2014 ($ millions)
  • Exhibit 17: YoY Growth and Revenue of Diovan 2010-2014 ($ millions)
  • Exhibit 18: YoY Growth and Revenue of Exforge 2010-2014 ($ millions)
  • Exhibit 19: YoY Growth and Revenue of Caduet 2010-2014 ($ millions)
  • Exhibit 20: YoY Growth and Revenue of Fragmin 2010-2014 ($ millions)
  • Exhibit 21: YoY Growth and Revenue of Lipitor 2010-2014 ($ millions)
  • Exhibit 22: YoY Growth and Revenue of Norvasc 2010-2014 ($ millions)
  • Exhibit 23: YoY Growth and Revenue of Lovenox 2010-2014 ($ millions)
  • Exhibit 24: YoY Growth and Revenue of Plavix 2010-2014 ($ millions)
  • Exhibit 25: Global IHD Drugs Market: Key Takeaways
  • Exhibit 26: AstraZeneca plc: Business Segmentation by Revenue 2013
  • Exhibit 27: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 ($ millions)
  • Exhibit 28: AstraZeneca plc: Sales by Geography 2013
  • Exhibit 29: Bayer: Business segmentation by revenue 2014
  • Exhibit 30: Bayer: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 31: Bayer: Geographical segmentation by revenue 2014
  • Exhibit 32: Eli Lilly: Business Segmentation by Revenue 2013
  • Exhibit 33: Eli Lilly: Business Segmentation by Revenue 2012 and 2013 ($ millions)
  • Exhibit 34: Eli Lilly: Sales by Geography 2013
  • Exhibit 35: Novartis AG: Business Segmentation
  • Exhibit 36: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 37: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 38: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 39: Pfizer: Business segmentation by revenue 2014
  • Exhibit 40: Pfizer: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 41: Pfizer: Geographical segmentation by revenue 2014
  • Exhibit 42: Sanofi SA: Business Segmentation
  • Exhibit 43: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 44: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 45: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Back to Top